Natale Quartuccio, Giorgio Treglia, Marco Salsano, Maria Vittoria Mattoli, Barbara Muoio, Arnoldo Piccardo, Egesta Lopci and Angelina Cistaro
: results of a prospective multicenter trial. J Clin Oncol 2007; 25: 5435-41.
25. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Kim EE. Bone and softtissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology 2007; 245: 839-47.
26. Piperkova E, Mikhaeil M, Mousavi A, Libes R, Viejo-Rullan F, Lin H. Impact of PET and CT in PET/CT studies for staging and evaluating treatment response in bone and soft tissue sarcomas. Clin Nucl Med 2009; 34: 146-50.
Mario Ciliberto, Fabio Maggi, Giorgio Treglia, Federico Padovano, Lucio Calandriello, Alessandro Giordano and Lorenzo Bonomo
W, Li HT, Li C, Zhang YK, Xie B, et al. Whole-body diffusionweighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up? Magn Reson Imaging 2010; 28: 613-70.
52. Pfannenberg C, Aschoff P, Schanz S, Eschmann SM, Plathow C, Eigentler TK, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007; 43: 557-64.
53. Laurent V, Trausch G, Bruot
Carmelo Caldarella, Barbara Muoio, Maria Antonietta Isgrò, Emilio Porfiri, Giorgio Treglia and Luca Giovanella
25. Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fosså SD, Lilleby W. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 2011; 23: 339-43.
26. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer
Semra Ince, Kursat Okuyucu, Oguz Hancerliogulları, Engin Alagoz, Huseyin San and Nuri Arslan
imaging with 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography ( 18 F-FDG-PET/CT) is the most recent modality for this purpose. 3 18 F-FDG-PET/CT has been used for baseline staging, assessment of treatment response and restaging of CRC as in many other cancers and is concerned to be more sensitive and specific imaging method than routine tools in cases of dubious recurrence and/ or metastasis. 2 , 3
CEA is expressed by a lot of epithelial tumors and its serum levels may increase in non-malignant conditions such as inflammatory
Giorgio Treglia, Silvia Taralli, Marco Salsano, Barbara Muoio, Ramin Sadeghi and Luca Giovanella
1. Lin M, Koo JH, Abi-Hanna D. Management of patients following detection of unsuspected colon lesions by PET imaging. Clin Gastroenterol Hepatol 2011; 9: 1025-32.
2. Treglia G, Calcagni ML, Rufini V, Leccisotti L, Meduri GM, Spitilli MG, et al. Clinical significance of incidental focal colorectal (18)F-fluorodeoxyglucose uptake: our experience and a review of the literature. Colorectal Dis 2012; 14: 174-80.
3. Isobe K, Hata Y, Sakaguchi S, Takai Y, Shibuya K, Takagi K, et al. The role of positron
Zdenek Rehak, Andrea Sprlakova-Pukova, Zbynek Bortlicek, Zdenek Fojtik, Tomas Kazda, Marek Joukal, Renata Koukalova, Jiri Vasina, Jana Eremiasova and Petr Nemec
, additional imaging methods for assessing rheumatic diseases are warranted.
Prolonged febrile illness with concomittant non-specific symptoms can be also a sign of PMR as well as GCA. Thus, patients may be referred during differential diagnostics of inflammatory or malignant disease to whole body positron emission tomography (PET) or a combination of PET with computed tomography (PET/CT) using 18 F-fluorodeoxyglucose ( 18 F-FDG). 11 – 14 Both GCA and PMR have their own characteristic 18 F-FDG PET/CT features, which may occur in a non-mutually exclusive manner.
Tae Hee Kim, Mi Ran Kim, Yongsik Jung and Young-Sil An
The study was conducted to evaluate the effect of sex hormones on F-18 fluorodeoxyglucose (18F-FDG) uptake by normal ovaries.
Patients and methods
A total of 197 premenopausal women were included in this study. Based on 18F-FDG positron emission tomography/computed tomography (PET/CT) images obtained from these subjects, the association of ovarian 18F-FDG uptake with levels of sex hormones, including estradiol, progesterone, testosterone, follicle-stimulating hormone, and luteinizing hormone was investigated. We also analysed the relationship between the menstrual cycle and ovarian 18F-FDG uptake.
The highest ovarian 18F-FDG uptake occurred at 2 weeks after the onset of menstruation (median maximum standardized uptake value [SUVmax] = 3.40, median mean SUV [SUVmean] = 2.20), and the lowest ovarian 18F-FDG uptake was observed during the first week of the menstrual cycle (median SUVmax = 1.60, median SUVmean = 1.20). Ovarian 18F-FDG uptake was weakly positively correlated with progesterone levels (rho = 0.28, p < 0.001 for SUVmax, rho = 0.30, p < 0.001 for SUVmean), and this pattern was consistently observed in subjects in the follicular-phase group (rho = 0.29, p = 0.003 for both SUVmax and SUVmean) but not in subjects in the luteal-phase group.
Based on PET images, ovarian glucose metabolism in premenopausal women tended to increase slightly with increasing progesterone concentration.
Eun-Ha Moon, Seok Tae Lim, Yeon-Hee Han, Young Jin Jeong, Yun-Hee Kang, Hwan-Jeong Jeong and Myung-Hee Sohn
Background. The objective of the study was to compare the diagnostic efficacy of an integrated Fluorine-18 fluorodeoxyglucose (F-18 FDG) PET/CT-mammography (mammo-PET/CT) with conventional torso PET/CT (supine-PET/CT) and MR-mammography for initial assessment of breast cancer patients.
Patients and methods. Forty women (52.0 ± 12.0 years) with breast cancer who underwent supine-PET/CT, mammo- PET/CT, and MR-mammography from April 2009 to August 2009 were enrolled in the study. We compared the size of the tumour, tumour to chest wall distance, tumour to skin distance, volume of axillary fossa, and number of metastatic axillary lymph nodes between supine-PET/CT and mammo-PET/CT. Next, we assessed the difference of focality of primary breast tumour and tumour size in mammo-PET/CT and MR-mammography. Histopathologic findings served as the standard of reference.
Results. In the comparison between supine-PET/CT and mammo-PET/CT, significant differences were found in the tumour size (supine-PET/CT: 1.3 ± 0.6 cm, mammo-PET/CT: 1.5 ± 0.6 cm, p < 0.001), tumour to thoracic wall distance (1.8 ± 0.9 cm, 2.2 ± 2.1 cm, p < 0.001), and tumour to skin distance (1.5 ± 0.8 cm, 2.1 ± 1.4 cm, p < 0.001). The volume of axillary fossa was significantly wider in mammo-PET/CT than supine-PET/CT (21.7 ± 8.7 cm3 vs. 23.4 ± 10.4 cm3, p = 0.03). Mammo-PET/CT provided more correct definition of the T-stage of the primary tumour than did supine-PET/ CT (72.5% vs. 67.5%). No significant difference was found in the number of metastatic axillary lymph nodes. Compared with MR-mammography, mammo-PET/CT provided more correct classification of the focality of lesion than did MR-mammography (95% vs. 90%). In the T-stage, 72.5% of cases with mammo-PET/CT and 70% of cases with MRmammography showed correspondence with pathologic results.
Conclusions. Mammo-PET/CT provided more correct definition of the T-stage and evaluation of axillary fossa may also be delineated more clearly than with supine-PET/CT. The initial assessment of mammo-PET/CT would be more useful than MR-mammography because the mammo-PET/CT indicates similar accuracy with MR-mammography for decision of T-stage of primary breast tumour and more correct than MR-mammography for defining focality of lesion.
Dražen Huić, Andrea Mutvar, Sandra Kinda-Bašić, Igor Aurer, Martina Ciglar, Darko Grošev, Ivo Radman, Boris Labar and Damir Dodig
tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930-4.
Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793-800.
Lavely WC, Delbeke D, Greer JP, Morgan DS, Byrne DW, Price RR, et al. FDG PET in the follow-up management of patients with
Kursat Okuyucu, Sukru Ozaydın, Engin Alagoz, Gokhan Ozgur, Semra Ince, Fahrettin Guven Oysul, Ozlem Ozmen, Murat Tuncel, Mustafa Ozturk and Nuri Arslan
. It has been claimed in previous studies that extranodal lymphomas should be regarded as separate nosological entities. 6 Computed tomography (CT) is the most frequently used imaging modality in the management of patients with PEL. CT, 18-fluorodeoxyglucose positron emission tomography (FDG-PET) and FDG-PET/CT are used to stage PEL. FDG-PET is a superior imaging technique which proved its utility especially in oncologic field. It is able to show functional alterations that precede the anatomical changes. Integration of CT to FDG-PET combines anatomical detail with